TX-FLUENCE-BY-OSRAM
23.11.2021 13:32:12 CET | Business Wire | Press release
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today it has partnered with White Lion Holdings , the leading consultant providing complete solutions for new and aspiring cannabis growers in South Africa.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211123005520/en/
Fluence’s South African partners include local distributor The Lamphouse, the largest supplier of specialized lamps in Africa with more than 40 years of experience in numerous specialty lighting sectors, and White Lion Holdings, a company offering complete cannabis growing solutions and consultancy, led by CEO Cornel van der Watt. Van der Watt has served at the forefront of developing cannabis markets in the U.S., Canada, the Netherlands and Lesotho, and has consulted extensively in Australia.
“Local partnerships are a key factor in delivering fast and reliable solutions to growers. Our stellar partners know the choice of lighting supplier is crucial to delivering consistent, high-quality yields premium clients in the northern hemisphere require,” said Timo Bongartz, Fluence’s general manager for Europe, the Middle East and Africa (EMEA). “Van der Watt chose to partner with Fluence and our local partner The Lamphouse based on his experience with Fluence’s superior LED products and valuable support in various jurisdictions where he has historically consulted cannabis growers.”
According to Prohibition Partners’ African Cannabis Report™ , by 2023, Africa’s legal cannabis industry could be worth more than $7.1 billion annually, with South Africa alone contributing an estimated $1.7 billion per year. The South African government’s recognition of the industry as a key to economic revival mirrors Prohibition Partners’ assessment—the cannabis industry represents the potential to create between 10,000 -25,000 job opportunities in a country with the highest unemployment rate in the world.
“The African cannabis market holds incredible potential and we know we’ve found the right partner in White Lion Holdings. We’re proud to collaborate with such a trusted brand and to support the growers who are revolutionizing the South African cannabis market,” Bongartz continues.
As the cannabis industry continues to gain traction throughout the country and continent, White Lion Holdings suggests growers will not only need innovative technology at their fingertips, but evidence-backed cultivation practices that yield high-quality crops, improved yields and consistent growth patterns.
“We’re thrilled to partner with Fluence and its local partner The Lamphouse,” said Van der Watt, who is currently consulting and managing four commercial operations throughout South Africa with other operations in the pipeline. “The cannabis plant is highly photosensitive. We prefer natural lighting and South Africa has an advantage in this regard with ample, good quality natural light. By choosing the location of the greenhouse well, one can get up to 11 hours of natural light for free. Then, we integrate supplemental lighting into the facility to optimize crop yield.”
The South African market is still in its infancy. Through its partnership with White Lion Holdings, Fluence lighting solutions have been implemented at pre-licensed and licensed cannabis greenhouse and indoor facilities throughout the country.
“I am testing various lighting solutions all the time, but those tests only reaffirm my partnership with Fluence and its local partner The Lamphouse given each company’s superior quality and valuable support. Thanks to consistent lighting, I have been able to surpass production targets. That is only possible with superior lighting,” Van der Watt added.
To achieve longevity in an industry that can quickly become crowded with new technologies and cultivation solutions, investors and growers must ensure they partner with experts in their respective fields who are purpose-built to support cultivators for the long-term.
“The Fluence system all but eliminates lighting as a variable and delivers a high return on investment. Optimizing the correct lighting strategy for the correct application and layout is one of the critical components to successful crop,” said Glenn Morris, CEO of The Lamphouse.
For more information on Fluence, visit www.fluence.science .
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM, creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit www.fluence.science .
About Cornel van der Watt and White Lion Holdings
With over 29 years of international, large scale cannabis cultivation experience under his belt, the White Lion Cornel van der Watt is in a class of his own. His knowledge of all aspects of the cannabis industry and his connections in the global cannabis community are unparalleled. He has also been at the forefront of the cannabis movement in South Africa since inception.
Every path he has walked in his professional and personal life has led him back to the cannabis industry. This path traces back to his qualification in chemical engineering, experience in scientific glassblowing, expertise in cultivation abroad and locally, studies in tissue cultivation, cloning and genetics, his community upliftment work as well as training and consulting.
While Cornel has become a scientist, a geneticist, a businessman and Cannabis Supremo, at the heart of his consultancy lies a deep and spiritual connection with the cannabis plant. For more information about White Lion Holding, visit https://www.whitelionholdings.co.za .
About The Lamphouse
Established in 1976, The Lamphouse is the largest supplier and distributor of specialized lamps in Southern Africa. Over the past 40 years, The Lamphouse has developed strategic relationships with suppliers and customers alike, providing lighting applications for horticulture, medical solutions, stage and studio, airfield, navigation and more. The company is headquartered in Johannesburg, South Africa, with additional offices in Cape Town and Durban. For more information about The Lamphouse, visit https://www.thelamphouse.co.za .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211123005520/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom